![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BARR RECEIVES FDA APPROVAL FOR GENERIC XANAX
BARR RECEIVES FDA APPROVAL FOR GENERIC XANAX
August 1, 2006
Barr Laboratories has it received final approval from the FDA for its application to manufacture and market a generic version of Pfizer's Xanax XR (alprazolam extended-release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The company intends to launch its product immediately.
Xanax is indicated for the treatment of panic disorder, with or without agoraphobia. Barr's generic drug will compete in a market that had total annual sales of approximately $83 million for the twelve months ending May 2006, according to IMS sales data.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct